Results 71 to 80 of about 137,345 (233)

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Association of HHV-6 with Hodgkin and non Hodgkin lymphoma

Iranian Journal of Microbiology, 2016
Background and Objectives: Human Herpes 6 virus (HHV-6) could remain latent and chronic in the host cells after primary infection. HHV-6 genome encodes certain trans activation proteins which may results in development of malignantlymphoma.
Hadis Kiani, Manoochehr Makvandi, Alireza Samarbafzadeh, Ali Teimoori, Niloofar Neisi, Hamideh Mehravaran, Hashem Radmehr, Zeinab Hosseini, Azadeh Haghi, Toran Shahani, Mehran Varnaseri, Nastaran Ranjbari   +11 more
doaj  

Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas

Revista Brasileira de Hematologia e Hemoterapia, 2011
OBJECTIVE: To evaluate the use of high-dose sequential chemotherapy in a Brazilian population. METHODS: High-dose cyclophosphamide followed by autologous hematopoietic stem cell transplantation is an effective and feasible therapy for refractory/relapsed
Bruno Kosa Lino Duarte, Eliana Cristina Martins Miranda, Marcio Nucci, Afonso Celso Vigorito, Francisco José Penteado, José Francisco Comenalli Marques Jr, Gislaine Borba Oliveira-Duarte, Irene Gyongyver Heidemarie Lorand-Metze, Katia Borgia Pagnano, Marcia Torresan Delamain, Renata Baldissera, Isabella Salvetti Valente, Carmino Antonio de Souza   +12 more
doaj   +1 more source

Spectrum of malignancies among the population of adults living with HIV infection in China: A nationwide follow-up study, 2008-2011. [PDF]

, 2019
BackgroundAlthough increasingly studied in high-income countries, there is a paucity of data from the Chinese population on the patterns of cancer among people living with HIV (PLHIV).MethodsWe conducted a nationwide follow-up study using routinely ...
Detels, Roger, He, Na, Mao, Yurong, McGoogan, Jennifer M, Tang, Houlin, Wu, Zunyou, Zhang, Zuo-Feng, Zhu, Weiming   +7 more
core   +2 more sources

Consumed by Abdominal Distention

Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge, James Grenert, Brian Haas, Mary Margaretten   +3 more
wiley   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

The Broad Spectrum HDAC Inhibitor PCI-24781 Induces Caspase- and ROS-Dependent Apoptosis and is Synergistic with Bortezomib in Lymphoma [PDF]

, 2008
We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Andrew Evens, Joseph Buggy, Kevin David, Lauren Mauro, Leo Gordon, Mint Sirisawad, Richard Miller, Savita Bhalla, Sheila Prachand, Sriram Balasubramanian   +9 more
core   +1 more source

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, EarlyView.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma [PDF]

, 2016
Key Points Combining phosphatidylinositol-3-kinase δ inhibition with rituximab, bendamustine, or both is feasible and active in relapsed iNHL.
Barrientos, Jacqueline C., Boccia, Ralph V., Boyd, Thomas E., Coutre, Steven E., de Vos, Sven, Flinn, Ian W., Fowler, Nathan H., Furman, Richard R., Godfrey, Wayne R., Kim, Yeonhee, Leonard, John P., Rai, Kanti R., Schreeder, Marshall T., Sharman, Jeff P., Wagner-Johnston, Nina D.   +14 more
core   +2 more sources

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source